Founded in February 2022, Synaura develops and commercializes human milk oligosaccharides (HMOs) and other biologics for nutrition, biomedicine, agriculture and health-food markets. HMO is Synaura's core product in nutrition, with the company emphasizing high purity, low impurities and odorlessness achieved through in-house R&D and precise fermentation processes. The article notes regulatory momentum in China after the National Health Commission approved two HMO components (2'-Fucosyllactose and Lacto-N-neotetraose), and states Synaura is among the first domestic HMO suppliers approved and is described as the first Chinese enterprise to obtain GRAS certification in the HMO field; it is also identified as the first Chinese HMO company in the process of GRAS certification and novel food authorization. Product applications span multiple fields, and the company positions itself to meet customers' and consumers' demand for high-quality nutrition. Planned uses of new funds include new product research and development, laboratory construction, industrialization and commercial promotion, and Synaura intends to accelerate research and innovation, expand HMOs and new pipelines, and boost the professional influence of domestic HMOs to support the dairy industry's high-quality development.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024